Recent Advances in Methamphetamine Neurotoxicity Mechanisms and Its Molecular Pathophysiology
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Methamphetamine (METH) is a sympathomimetic amine that belongs to phenethylamine and amphetamine class of psychoactive drugs, which are widely abused for their stimulant, euphoric, empathogenic, and hallucinogenic properties. Many of these effects result from acute increases in dopamine and serotonin neurotransmission. Subsequent to these acute effects, METH produces persistent damage to dopamine and serotonin release in nerve terminals, gliosis, and apoptosis. This review summarized the numerous interdependent mechanisms including excessive dopamine, ubiquitin-proteasome system dysfunction, protein nitration, endoplasmic reticulum stress, p53 expression, inflammatory molecular, D 3 receptor, microtubule deacetylation, and HIV-1 Tat protein that have been demonstrated to contribute to this damage. In addition, the feasible therapeutic strategies according to recent studies were also summarized ranging from drug and protein to gene level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Astrocytes: Biology and pathology
Sofroniew, M. V., & Vinters, H. V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0619-8 · Cited by 5,196 · cited 1×
“METH generates an imbalance in the release and reuptake of dopamine, norepinephrine, and epinephrine producing intense euphoria followed by hours of stimulation, excitation, and alertness [6].”
BackgroundMicroglia: a sensor for pathological events in the CNS
Kreutzberg, G. W. (1996) · Trends in Neurosciences · doi:10.1016/0166-2236(96)10049-7 · Cited by 4,396 · cited 1×
“following brain injury in general [64, 65], and primarily in the dopamine-rich striatum in brain of experimental animals exposed to high doses ofMETH [8, 66, 67], the latest research”
BackgroundFamilial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024
The endocannabinoid system and the brain.
Mechoulam, R., & Parker, L. A. (2013) · Annual Review of Psychology · doi:10.1146/annurev-psych-113011-143739 · Cited by 1,090 · cited 1×
“The endocannabinoid system (ECS) is an endogenous neuromodulatory system, which has been shown to participate in a broad range of functions including anxiety, depression, neurogenesis, reward, cognition, learning, and memory [142].”
BackgroundZhang, Y., Gao, J., Chung, K. K. K., Huang, H., Dawson, V. L., & Dawson, T. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.240347797 · Cited by 982
The Promise of Minocycline in Neurology
Yong, V. W., Wells, J., Giuliani, F., Casha, S., Power, C., & Metz, L. M. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00937-8 · Cited by 518
Invited Review Free radicals and the pathobiology of brain dopamine systems
Cadet, J. L., & Brannock, C. (1998) · Neurochemistry International · doi:10.1016/s0197-0186(97)00031-4 · Cited by 499
Yu, Z., Luo, H., Fu, W., & Mattson, M. P. (1999) · Experimental Neurology · doi:10.1006/exnr.1998.7002 · Cited by 438
Methamphetamine use: A comprehensive review of molecular, preclinical and clinical findings
Panenka, W. J., Procyshyn, R. M., Lecomte, T., MacEwan, G. W., Flynn, S. W., Honer, W. G., & Barr, A. M. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.11.016 · Cited by 432 · cited 1×
“Methamphetamine (METH) is a kind of highly addictive psychostimulant drug that principally affects themonoamine neurotransmitter systems of the brain and results in feelings of alertness, increasing energy, and euphoria [1].”
BackgroundMethamphetamine causes microglial activation in the brains of human abusers
Sekine, Y., Ouchi, Y., Sugihara, G., Takei, N., Yoshikawa, E., Nakamura, K., Iwata, Y., Tsuchiya, K. J., Suda, S., Suzuki, K., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1179-08.2008 · Cited by 381 · cited 1×
“Interestingly, such inflammatory processes appear to be part of METH-induced toxicity, because this drug stimulates microglial activation in dopaminergic regions such as the striatum [149] and increases TNF-α levels [21].”
BackgroundOxidative and nitrosative stress in Parkinson's disease
Tsang, A. H. K., & Chung, K. K. K. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.12.006 · Cited by 300 · cited 1×
“In a variety of neurodegenerative diseases, such as PD and Alzheimer’s (AD), protein tyrosine nitration has been indicated as a salient feature of the pathological mechanism [93, 94].”
BackgroundCadet, J. L., Jayanthi, S., & Deng, X. (2003) · The FASEB Journal · doi:10.1096/fj.03-0073rev · Cited by 286
Jiang, H., Ren, Y., Yuen, E. Y., Zhong, P., Ghaedi, M., Hu, Z., Azabdaftari, G., Nakaso, K., Yan, Z., & Feng, J. (2012) · Nature Communications · doi:10.1038/ncomms1669 · Cited by 254
Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers
Johanson, C.-E., Frey, K. A., Lundahl, L. H., Keenan, P., Lockhart, N., Roll, J., Galloway, G. P., Koeppe, R. A., Kilbourn, M. R., Robbins, T., et al. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0330-6 · Cited by 233
Role of Tumor Necrosis Factor-α in Methamphetamine-Induced Drug Dependence and Neurotoxicity
Nakajima, A., Yamada, K., Nagai, T., Uchiyama, T., Miyamoto, Y., Mamiya, T., He, J., Nitta, A., Mizuno, M., Tran, M. H., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4847-03.2004 · Cited by 176
Ladenheim, B., Krasnova, I. N., Deng, X., Oyler, J. M., Polettini, A., Moran, T. H., Huestis, M. A., & Cadet, J. L. (2000) · Molecular Pharmacology · doi:10.1124/mol.58.6.1247 · Cited by 131 · cited 4×
“Cadet and colleagues reported that METH-induced neurotoxicity and gliosis were attenuated in IL-6 knockout mice [37] and that METH injection increased the expression of transcription factorNF-AT,which promotes IL-4 expression [38].”
BackgroundInfluentialSuppression of autophagy precipitates neuronal cell death following low doses of methamphetamine
Castino, R., Lazzeri, G., Lenzi, P., Bellio, N., Follo, C., Ferrucci, M., Fornai, F., & Isidoro, C. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05488.x · Cited by 115
Minocycline: Neuroprotective Mechanisms in Parkinsons Disease
Thomas, M., & Le, W. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043453162 · Cited by 114
Flora, G., Lee, Y. W., Nath, A., Hennig, B., Maragos, W., & Toborek, M. (2003) · Experimental Neurology · doi:10.1006/exnr.2002.8048 · Cited by 99
Amphetamine releases dopamine from synaptic vesicles by dual mechanisms
Floor, E., & Meng, L. (1996) · Neuroscience Letters · doi:10.1016/s0304-3940(96)12963-3 · Cited by 54
Cited by
Neurobiology, Clinical Presentation, and Treatment of Methamphetamine Use Disorder: A Review
Paulus, M. P., & Stewart, J. L. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.0246 · Cited by 310
Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder
Brett, J., Knock, E., Korthuis, P. T., Liknaitzky, P., Murnane, K. S., Nicholas, C. R., Patterson, J. C., & Stauffer, C. S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1123424 · Cited by 16
Metadata
- Authors
- Yu, S., Zhu, L., Shen, Q., Bai, X., & Di, X.
- Venue
- Behavioural Neurology
- Publisher
- Wiley
- Published
- 2015
- Volume
- 2015
- Pages
- 1-11
- ISSN
- 0953-4180 (ISSN-L)
- 1875-8584
- OpenAlex
- W1973393483
- Cited by
- 175
- References
- 20
- FWCI
- 9.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.